Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 54.2%

Gross margin was 54.2% in Q2 FY2026, down 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 54.5%, up 1.4 pp year over year. Over 3 fiscal years it narrowed by 35.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
54.2%-0.9 pp QoQ
Last fiscal yearDec 2025
54.6%-31.0 pp YoY
LTMJun 2026
54.5%+1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.5 pp——
1 year-31.0 pp——
3 years-35.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
54.6%
Year-over-year change
-31.0pp

Gross Margin vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 gross margin of 54.5% is the 7th highest of the 9 companies compared; the peer median is 86.9%.
  • Its year-over-year change of +1.4 pp is the 4th highest of 7, against a peer median of +27.0 pp.
  • Over three fiscal years its change of -35.0 pp compares with a peer median of +16.3 pp.
KNSA Competitors Peer median
Gross Margin for KNSA and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
IMVTImmunovant, Inc.LTM Sep 2026100.0% ——
DNTHDianthus Therapeutics, Inc.LTM Jun 202696.0% -4.0 pp+0.0 pp
PHARPharming Group N.V.LTM Mar 202687.3% -1.7 pp-3.6 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 202654.5% +1.4 pp-35.0 pp
SYRESpyre Therapeutics, Inc.LTM Sep 202650.0% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
ORKAOruka Therapeutics, Inc.FY2025— ——
Peer median (excluding KNSA) 86.9%+27.0 pp+16.3 pp

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.54M220.18M270.26M423.24M677.56M
Cost of Revenue9.1M22.9M56.52M60.91M307.41M
Gross Profit29.44M197.29M213.74M362.33M370.15M
Gross Margin76.4%89.6%79.1%85.6%54.6%
Research & Development99.3M65.49M76.1M111.62M96.85M
Selling, General & Admin85.95M97.95M129.43M168.01M196.27M
Operating Expenses186.08M187.51M238.93M407.95M292.93M
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
EBITDA(154.18M)13.43M(14.31M)(34.46M)90.42M
EBITDA Margin-400.0%6.1%-5.3%-8.1%13.3%
Operating Income(156.64M)9.77M(25.2M)(45.62M)77.22M
Operating Margin-406.4%4.4%-9.3%-10.8%11.4%
Interest Income97K1.25M8.54M9.46M11.65M
Interest Expense00000
Other Income / Expenses97K1.25M8.54M9.46M11.65M
Income Before Tax(156.54M)11.03M(16.65M)(36.15M)88.87M
Pre-Tax Margin-406.1%5.0%-6.2%-8.5%13.1%
Income Tax Expense1.39M(172.34M)(30.74M)7.04M29.86M
Net Income(157.92M)183.36M14.08M(43.19M)59.01M
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (Basic)(2.30)2.640.20(0.60)0.80
EPS (Diluted)(2.30)2.600.20(0.60)0.75
Weighted Avg Shares68.58M69.38M70.06M71.42M74.2M
Weighted Avg Shares (Diluted)68.58M70.42M71.92M71.42M78.98M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.